Stimulation Of NK1 Receptors Research Articles

Substance P reduces TNF-α-induced apoptosis in human tenocytes through NK-1 receptor stimulation

BackgroundIt has been hypothesised that an upregulation of the neuropeptide substance P (SP) and its preferred receptor, the neurokinin-1 receptor (NK-1 R), is a causative factor in inducing tenocyte hypercellularity,...

Inflammatory cells as source of tachykinin-induced mucus secretion in chronic bronchitis

Substance P and neurokinin A are regulatory peptides of the tachykinin family that influence many aspects of human airway function in health and diseases such as bronchial asthma or chronic obstructive pulmonary disease (COPD). Tachykinin-induced mucus secretion has been regarded as sensory nerve-dependent so far. We studied the distribution of tachykinin-mRNA and -peptide and its relation to NK-1 subtype-positive cells in human airway glands to assess if tachykinins may also be expressed in inflammatory cells. RT-PCR demonstrated the expression of tachykinin- and NK-1-mRNA in human airway tissues. In situ hybridisation resulted in preprotachykinin (PPT)-A mRNA-signal detection in inflammatory cells which were in close contact to myoepithelial cells of airway glands. NK-1 immunoreactivity was found in myoepithelial cells which were in direct contact to the PPT-A mRNA and tachykinin-positive cells. The present data directly demonstrate the presence of both PPT-A mRNA and tachykinin immunoreactivity in inflammatory airway cells which are in direct contact to NK-1 receptor positive glandular myoepithelium. Our findings indicate that besides neurally released tachykinins, also inflammatory cell-derived tachykinins may lead to glandular secretion via NK-1 receptor stimulation. This points to a major second source of these proinflammatory mediators in chronic inflammatory airway diseases such as COPD or asthma.

Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.

Tachykinin NK2 receptors are expressed in the gastrointestinal tract of both laboratory animals and humans. Experimental data indicate a role for these receptors in the regulation of intestinal motor functions (both excitatory and inhibitory), secretions, inflammation and visceral sensitivity. In particular, NK2 receptor stimulation inhibits intestinal motility by activating sympathetic extrinsic pathways or NANC intramural inhibitory components, whereas a modulatory effect on cholinergic nerves or a direct effect on smooth muscle account for the NK2 receptor-mediated increase in intestinal motility. Accordingly, selective NK2 receptor antagonists can reactivate inhibited motility or decrease inflammation- or stress-associated hypermotility. Intraluminal secretion of water is increased by NK2 receptor agonists via a direct effect on epithelial cells, and this mechanism is active in models of diarrhoea since selective antagonists reverse the increase in faecal water content in these models. Hyperalgesia in response to intraluminal volume signals is possibly mediated through the stimulation of NK2 receptors located on peripheral branches of primary afferent neurones. NK2 receptor antagonists reduce the hyper-responsiveness that occurs following intestinal inflammation or application of stressful stimuli to animals. Likewise, NK2 receptor antagonists reduce intestinal tissue damage induced by chemical irritation of the intestinal wall or lumen. In healthy volunteers, the selective NK2 antagonist nepadutant reduced the motility-stimulating effects and irritable bowel syndrome-like symptoms triggered by intravenous infusion of neurokinin A, and displayed other characteristics that could support its use in patients. It is concluded that blockade of peripheral tachykinin NK2 receptors should be considered as a viable mechanism for decreasing the painful symptoms and altered bowel habits of irritable bowel syndrome patients.

The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.

Noradrenaline (NA), a key neurotransmitter of the endogenous pain inhibitory system, acutely inhibits nociceptive transmission (including that mediated by substance P), potentiates opioid analgesia, and underlies part of the antinociceptive effects of the widely prescribed tricyclic antidepressants. Lesions of noradrenergic neurons, however, result in either normal or reduced pain behavior and variable changes in morphine antinociception, undermining the proposed association between noradrenaline (NA) deficiency and chronic pain (hyperalgesia). We used mice lacking the gene coding for dopamine beta-hydroxylase, the enzyme responsible for synthesis of NA from dopamine, to reexamine the consequences of a lack of NA on pain behavior. Here, we show that absence of NA in the central nervous system results in a substance P-mediated chronic hyperalgesia (decreased nociceptive threshold) to thermal, but not mechanical, stimuli and decreased efficacy of morphine. Contrary to studies that show substance P-mediated hyperalgesia requires intense stimuli, we found that even a mild stimulus is sufficient to evoke substance P-dependent hyperalgesia in the NA-deficient mice. Restoring central NA normalized both the nociceptive threshold and morphine efficacy, which is consistent with a tonic inhibitory effect of NA on nociceptive transmission. Unexpectedly, however, antagonists to the substance P receptor (the NK1 receptor) could achieve the same effect as NA replacement. We conclude that when unopposed by NA, substance P acting at the NK1 receptor causes chronic thermal hyperalgesia, and that the reduced opioid efficacy associated with a lack of NA is due to increased NK1-receptor stimulation.

Tachykinin activation of human monocytes from patients with rheumatoid arthritis: in vitro and ex-vivo effects of cyclosporin A

Three types of tachykinin receptors, namely NK1, NK2and NK3, are known to preferentially interact with substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), respectively. We previously demonstrated that NK1and NK2receptors are present on human monocytes, SP and NKA inducing superoxide anion production and tumor necrosis factor- alpha (TNF-α) mRNA expression. NK2receptor stimulation also triggered an enhanced respiratory burst in monocytes isolated from rheumatoid arthritis (RA) patients. This study was aimed to evaluate the in vitro and ex-vivo effects of cyclosporin A (CsA) on tachykinins-evoked TNF-α release from monocytes of healthy donors and RA patients. CsA (100ng/ml) potently inhibited phorbol ester- and tachykinin-evoked TNF-α secretion. In RA patients treated with CsA (SandimmunRNeoralR) 2.5mg/kg/die, a significant time-dependent reduction in TNF-α secretion from monocytes was measured. This may contribute to the CsA therapeutic activity in RA.

Participation of Neuropeptides in Antigen-Induced Contraction of Guinea Pig Bronchi via NK2 but Not NK1 Receptor Stimulation

We evaluated the contribution of neuropeptides to antigen-induced contractions of isolated bronchi and tracheae of passively sensitized guinea pigs using CP-96345 and SR 48968, specific antagonists of NK₁ and NK₂ receptors, respectively, in combination with treatment by an antihistaminic and a cysteinyl leukotriene antagonist. SR-48968 but not CP-96345, significantly inhibited the late phase of the bronchial contraction. Phosphoramidon, a neutral endopeptidase inhibitor, tended to potentiate bronchial contraction. Posttreatment with SR-48968 decreased the enhanced contraction induced by the inhibitor as well as the nonenhanced contraction to similar levels of tension. On the other hand, antigen-induced tracheal contraction was not altered by either neuropeptide antagonist. These results suggest that neuropeptides mediate the antigen-induced contractile response of the guinea pig bronchus partly through NK₂ receptor stimulation.

Pro-inflammatory effects of substance P: new perspectives for the treatment of airway diseases?

Non-adrenergic, non-cholinergic (i.e. NANC) neuronal transmission has been implicated in the pathophysiology of asthma. Attention has focused on both inhibitory NANC transmission mediated by its putative neurotransmitters vasoactive intestinal peptide (VIP) and nitric oxide (NO) and excitatory NANC transmission mediated by the sensory neuropeptides. Studies on rodent airway and non-airway tissue have demonstrated that activation of non-cholinergic excitatory nerves by mechanical or chemical stimuli can generate local axon reflexes that lead to bronchoconstriction and neurogenic inflammation. The sensory neuropeptides substance P (SP) and neurokinin A (NKA) have various effects that could contribute to changes observed in asthmatic airways, including smooth muscle contraction, submucosal gland secretion, vasodilatation, an increase in vascular permeability, stimulation of cholinergic nerves and stimulation of immune cells 1 Bertrand C. Geppetti P. Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease. Trends Pharmacol. Sci. 1996; 17: 255-259 Abstract Full Text PDF PubMed Scopus (81) Google Scholar , 2 Joos G.F. et al. Sensory neuropeptides and the human lower airways: present state and future directions. Eur. Respir. J. 1994; 7: 1161-1171 PubMed Google Scholar . Most of these effects have been observed in both human and animal tissue and are mediated by specific tachykinin receptors; stimulation of the NK2 receptor mediates a major part of the tachykinin-induced airway smooth muscle contraction, whereas stimulation of NK1 receptors induces vasodilatation, plasma protein extravasation, mucus secretion and stimulation of inflammatory and immune cells 3 Advenier C. et al. Role of tachykinins as contractile agonists of human airways in asthma. Clin. Exp. Allergy. 1999; 29: 579-584 Crossref PubMed Scopus (31) Google Scholar . The effects of tachykinins on the airways can be terminated by enzymatic degradation, mainly by the action of the ectoenzyme neutral endopeptidase 2 Joos G.F. et al. Sensory neuropeptides and the human lower airways: present state and future directions. Eur. Respir. J. 1994; 7: 1161-1171 PubMed Google Scholar . (2s-cis)-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine ((+)-(2s,3s)-3-methoxybenzyl amino)-2-phenylpiperidine N-[N2-[N-[N-[N-[2,3-didehydro-N-methyl-N-[N-[3-(2-pentylphenyl)-propionyl]-l-threonyl]tyrosyl-l-leucynyl]-d-phenylalanyl]-l-allothreonyl]-l-asparaginyl]-l-serine-n-lactone] N2-[(4r)-4-hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-l-prolyl]-N-phenylmethyl-3-(2-naphthyl)-l-alaninamide (s)-N-methyl-N[4-(4-acetylamino-4-phenyl piperidino)-2-(3,4-dichlorophenyl)butyl] benzamide

Tachykinin activation of human monocytes from patients with interstitial lung disease, healthy smokers or healthy volunteers

Three types of tachykinin receptors, NK1, NK2and NK3, have been described to preferentially interact with substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) respectively. Experimental evidence indicates that SP and NKA modulate the activity of inflammatory and immune cells, including mononuclear ones, and points to their involvement in lung pathophysiology. We previously reported that NK1and NK2receptors are present on monocytes (MO) isolated from healthy donors or rheumatoid patients – a greater sensitivity to NK2receptor stimulation was observed in the latter condition. This study evaluated the effects of SP and NKA, as well as NK1and NK2selective agonists and antagonists, on MO obtained from healthy volunteers, healthy smokers or patients with interstitial lung diseases (e.g. sarcoidosis and idiopathic pulmonary fibrosis). Superoxide anion (O2–) production was chosen as a parameter of cell activation. SP and NKA dose-dependently evoked O2–production from MO in all the conditions evaluated, their effects being competitively antagonized by selective antagonists (CP 96 345 and MEN 10 627, respectively). When selective NK1and NK2agonists were used, [Sar9Met(O2)11]SP, a selective NK1agonist, induced a more than doubled O2production in MO obtained from patients with interstitial lung diseases as compared to healthy volunteers, whereas MO isolated from healthy volunteers were more sensitive to NK2receptor stimulation.

Actions of Tachykinins Within the Heart and Their Relevance to Cardiovascular Disease

Substance P and neurokinin A are tachykinins that are co-localized with calcitonin gene-related peptide (CGRP) in a unique subpopulation of cardiac afferent nerve fibers. These neurons are activated by nociceptive stimuli and exhibit both sensory and motor functions that are mediated by the tachykinins and/or CGRP. Sensory signals (e.g., cardiac pain) are transmitted by peptides released at central processes of these neurons, whereas motor functions are produced by the same peptides released from peripheral nerve processes. This review summarizes our current understanding of intracardiac actions of the tachykinins. The major targets for the tachykinins within the heart are the intrinsic cardiac ganglia and coronary arteries. Intrinsic cardiac ganglia contain cholinergic neurons that innervate the heart and coronary vasculature. Tachykinins can stimulate NK3 receptors on these neurons to increase their excitability and evoke spontaneous firing of action potentials. This action provides a mechanism whereby tachykinins can indirectly influence cardiac function and coronary tone. Tachykinins also have direct effects on coronary arteries to decrease or increase tone. Stimulation of NK1 receptors on the endothelium causes vasodilation mediated by nitric oxide. This effect is normally dominant, but NK2 receptor-mediated vasoconstriction can also occur and is augmented when NKi receptors are blocked. It is proposed that these ganglion stimulant and vascular actions are manifest by endogenous tachykinins during myocardial ischemia.

Tachykinin NK1receptor-mediated inhibitory responses in the guinea-pig small intestine

We used in vivo, in vitro studies and immunohistochemistry to elucidate the mechanisms activated by tachykinin NK1receptors in evoking inhibitory motor response in the guinea-pig small intestine. In vivo, the selective NK1receptor agonist GR 73,632 produced a dose-dependent suppression of the distension-induced duodenal contractions, and a decrease of basal tone. These effects were reduced by pretreatment with the NK1receptor antagonist SR 140,333. In L-Nω-nitro-L-arginine methylesther hydrochloride-pretreated animals, the suppressant effect of GR 73,632 on duodenal contractions was reduced, whereas the relaxation of the basal tone was unaffected. In vitro, GR 73,632 evoked a biphasic response consisting of a transient, tetrodotoxin-sensitive inhibitory effect followed by tetrodotoxin-resistant contractions. SR 140,333 blocked both inhibitory and excitatory motor responses induced by GR 73,632. NK1immunoreactivity was localized to myenteric and submucosal neurons and to interstitial cells of Cajal in the deep muscular plexus of the small intestine. NK1receptor-expressing neurons had Dogiel type I morphology and many of them were β-nicotinamide adenine phosphate dinucleotide-diaphorase-positive, indicating they are inhibitory neurons. In conclusion, in the guinea-pig small intestine, NK1receptor stimulation evokes a myogenic excitatory motor response and a neurogenic inhibitory motor response that involves, at least in part, a nitrinergic pathway.

Effects of SR 140333 and SR 48968 on antigen and substance P-induced activation of guinea-pig alveolar macrophages.

Tachykinins, such as substance P, might be involved in the development of airway hyperresponsiveness and airway inflammation. This study was designed to investigate the effects of the tachykinin NK1 receptor antagonist SR 140333 (Nolpitantium) and the NK2 receptor antagonist SR 48968 (Saredutant) on the activation of alveolar macrophages in the guinea-pig. Guinea-pigs sensitized and challenged by ovalbumin administered by aerosol or naive guinea-pigs were exposed by aerosol to the neutral endopeptidase, phosphoramidon and, 15 min later, to substance P. Twenty-four hours later, bronchoalveolar lavages were performed and the cell composition of bronchoalveolar lavage fluids and the arachidonate release from alveolar macrophages stimulated in vitro with fMLP were evaluated. Antigen challenge in sensitized guinea-pigs induced an increase in the total number of cells and granulocytes in the bronchoalveolar lavage fluids that was not reduced by pre-treatment of guinea-pigs with a single dose of SR 140333 or SR 48968 (1 mg/kg). Substance P exposure in phosphoramidon-pretreated guinea-pigs did not induce an increase in the total number of cells. In contrast, antigen or substance P exposure induced a significant increase in the in vitro fMLP-induced arachidonate release from alveolar macrophages. Pre-treatment of the guinea pigs with SR 140333 or SR 48968 did not reduce the increase in arachidonate release from fMLP-stimulated alveolar macrophages from sensitized and challenged guinea-pigs. Pre-treatment of the animals by SR 140333 and SR 48968 reduced the enhanced arachidonate release induced by fMLP from substance P-exposed guinea-pigs. The present data demonstrate the importance of NK1- and NK2-receptor stimulation in the development of substance P-induced increased reactivity of alveolar macrophages.

Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis

Three types of tachykinin receptors, namely NK1, NK2 and NK3, are known to preferentially interact with substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), respectively. Experimental evidence indicates that SP and NKA modulate the activity of inflammatory and immune cells, including mononuclear ones. This study evaluated the effects of mammalian tachykinins and selective tachykinin agonists and antagonists on human monocytes isolated from healthy donors: SP, NKA and NKB all evoked a dose-dependent superoxide anion (O2-) production and the NK2 selective agonist [beta-Ala8]-NKA(4-10) induced a full response. The NK3 selective agonist senktide was inactive, while the NK1 selective agonists septide and [Sar9Met(O2)11]SP displayed some effects. These results indicate that NK2 and also some NK1 receptors are present in monocytes isolated from healthy donors. The role of tachykinin receptor activation in rheumatoid arthritis was also investigated, by measuring O2- production and TNF-alpha mRNA expression in monocytes isolated from rheumatoid patients. Tachykinins enhanced the expression of this cytokine in both control and rheumatoid monocytes and NK2 receptor stimulation was shown to trigger an enhanced respiratory burst in monocytes from rheumatoid patients. In conclusion, these results indicate that NK2 and NK1 receptors are present on human monocytes, the former being preferentially involved in rheumatoid arthritis.

The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough.

Several recent observations suggest that tachykinins, such as substance P and neurokinin A, might be involved in the pathogenesis of bronchopulmonary alterations. Progress in investigations on the physiological and pathological roles of tachykinins has been greatly facilitated by the availability of a number of highly selective nonpeptide antagonists for tachykinin neurokinin 1, 2 and 3 (NK1, NK2 and NK3) receptors. The use of selective tachykinin NK2 receptor antagonists suggests that tachykinin NK2 receptor stimulation plays an important role in the development of airway hyperresponsiveness in the guinea-pig. Others studies have also indicated that tachykinin NK1-receptors are involved in immediate or delayed neurogenic inflammation including microvascular leakage and the subsequent increase in plasma protein extravasation. A role for the sensory neuropeptide system has also been proposed in cough, as shown by the observation that the antitussive effect of tachykinin NK2 receptor antagonists has clearly been demonstrated in several experimental conditions, but the effect of tachykinin NK1 receptor antagonists is still debated. Taken together, the results obtained with the various selective receptor antagonists provide pharmacological evidence that tachykinins play a role in delayed bronchopulmonary alterations and suggest that tachykinin receptor antagonists may be useful for investigating mechanisms and possibly reducing airway functional alterations in asthmatic patients.

Substance P analogues potentiate the pressor response to microinjection of l-glutamate into laminas I and II of the cat dorsal horn

Microinjection of a substance P analogue (1 mM; 7 or 10 nl) into laminae I and II of the L 7 dorsal horn of decerebrate cats significantly potentiated ( P<0.05) the increase in arterial pressure evoked by microinjection of l-glutamate (109 mM; 7 or 10 nl) into these spinal sites. Microinjection of the substance P analogues (i.e., GR73638 and [Sar 9,Met(O 2) 11]-substance P) which were selective NK-1 receptor agonists, had no impact on the cardioacceleration evoked by microinjection of l-glutamate ( P>0.05). In addition, microinjection of these analogues had no effect on the modest and non-significant increase in phrenic nerve discharge evoked by l-glutamate. We conclude that stimulation of NK-1 receptors in the superficial laminae of the dorsal horn potentiates the pressor responses to microinjection of l-glutamate.

Role of tachykinin NK1 and NK2 receptors on colonic motility in anesthetized rats: effect of agonists

Tachykinins fulfill general criteria to be considered as neurotransmitters-neuroeffectors in the mammalian enteric nervous system; however, little information is available about their role in the regulation of intestinal motility in vivo. The present study investigates the effect of selective tachykinin receptor agonists on colonic motility in urethane-anesthetized rats. Colonic motility was recorded by means of a balloon-catheter device (filled with 0.5 mL of water) inserted for 7 cm through the rectum. In atropine- and guanethidine-pretreated rats, the NK1 receptor agonist [Sar9]substance P sulfone (0.3-300 nmol/kg i.v.) dose dependently induced phasic contractions followed by an enhancement in the amplitude and frequency of spontaneous contractions. In three of six cases, a transient inhibition (3-5 min) of spontaneous motility was also evident after the phasic contraction. All these effects were reduced by the NK1 receptor antagonist SR 140333 (1 mumol/kg i.v.). In atropine- and guanethidine-pretreated rats and in the presence of SR 140333 (1 mumol/kg i.v.), the NK2 receptor agonist [beta-Ala8]neurokinin A-(4-10) (0.3-300 nmol/kg i.v.) induced a dose-dependent tonic contraction, but the amplitude and frequency of spontaneous contractions were not changed. NK2 receptor antagonists such as MEN 11420 (0.01-1 mumol/kg i.v.), MEN 10627 (1 mumol/kg i.v.), or SR 48968 (1 mumol/kg i.v.) reduced the effect of [beta-Ala8]neurokinin A-(4-10). The present results indicate that NK2 receptor stimulation evokes a pure excitatory effect on colonic motility whereas NK1 receptor stimulation induces both excitatory and inhibitory effects.

Role of tachykinin NK&lt;SUB&gt;1&lt;/SUB&gt; and NK&lt;SUB&gt;2&lt;/SUB&gt; receptors on colonic motility in anesthetized rats: effect of agonists

Tachykinins fulfill general criteria to be considered as neurotransmitters-neuroeffectors in the mammalian enteric nervous system; however, little information is available about their role in the regulation of intestinal motility in vivo. The present study investigates the effect of selective tachykinin receptor agonists on colonic motility in urethane-anesthetized rats. Colonic motility was recorded by means of a balloon-catheter device (filled with 0.5 mL of water) inserted for 7 cm through the rectum. In atropine- and guanethidine-pretreated rats, the NK1 receptor agonist [Sar9]substance P sulfone (0.3-300 nmol/kg i.v.) dose dependently induced phasic contractions followed by an enhancement in the amplitude and frequency of spontaneous contractions. In three of six cases, a transient inhibition (3-5 min) of spontaneous motility was also evident after the phasic contraction. All these effects were reduced by the NK1 receptor antagonist SR 140333 (1 mumol/kg i.v.). In atropine- and guanethidine-pretreated rats and in the presence of SR 140333 (1 mumol/kg i.v.), the NK2 receptor agonist [beta-Ala8]neurokinin A-(4-10) (0.3-300 nmol/kg i.v.) induced a dose-dependent tonic contraction, but the amplitude and frequency of spontaneous contractions were not changed. NK2 receptor antagonists such as MEN 11420 (0.01-1 mumol/kg i.v.), MEN 10627 (1 mumol/kg i.v.), or SR 48968 (1 mumol/kg i.v.) reduced the effect of [beta-Ala8]neurokinin A-(4-10). The present results indicate that NK2 receptor stimulation evokes a pure excitatory effect on colonic motility whereas NK1 receptor stimulation induces both excitatory and inhibitory effects.

Tachykinin Receptor Antagonists and Cough

Several potent and selective antagonists for tachykinin receptors are now available and appear as powerful tools to investigate the physiological and pathological roles of tachykinins and to identify the type of receptor involved in their effect. Indeed, a lot of studies have shown that tachykinin NK2receptor antagonists (SR 48968, MEN 10627) are able to inhibit cough induced by citric acid, capsaicin or allergen challenge in the unanesthetized guinea-pig or mechanical stimulation of the trachea in the cat. The effects of tachykinin NK1receptor antagonists are still debated, whereas an inhibitory effect of SR 142801, a tachykinin NK3receptor antagonist, has been reported against citric acid-induced cough in the guinea-pig. Experiments with tachykinin receptor antagonists which do not cross the blood brain barrier suggest that the site of action of tachykinin receptor antagonists is most probably peripheral, but a central action, at least in an area not protected by the blood brain barrier, cannot be excluded. Finally, tachykinin NK2receptor stimulation seems to be involved in sensitisation of cough reflex.

Effect of niflumic acid on electromechanical coupling by tachykinin NK1 receptor activation in rabbit colon

We have investigated the effect of the Cl− channel blocker, niflumic acid, on the contractile response and electromechanical coupling activated by stimulation of the tachykinin NK1 receptor in the longitudinal muscle of rabbit proximal colon, in the presence of indomethacin (5 μM). The application of submaximal equieffective concentrations of the tachykinin NK1 receptor-selective agonist [Sar9]substance P sulfone (30 nM), of carbachol (300 nM) and KCl (40 mM0, produced distinct phasic and tonic components of contraction. Niflumic acid (10–100 μM) preferentially and markedly inhibited the tonic component of the response to [Sar9]substance P sulfone and to carbachol, without affecting the response to KCl. Nifedipine (1 μM) abolished the response to KCl and greatly reduced the response to [Sar9]substance P sulfone and carbachol. The nifedipine-resistant response to [Sar9]substance P sulfone was attenuated by niflumic acid (100 μM), while that to carbachol was unaffected. In sucrose gap experiments, superfusion with niflumic acid (100 μM), in the presence of nifedipine (3 μM), produced membrane hyperpolarization, which was totally blocked by tetraethylammonium (10 mM). Niflumic acid inhibited both depolarization and contraction induced by [Sar9]substance P sulfone, both in the absence or in the presence of tetraethylammonium. The present findings support the idea that a niflumic acid-sensitive mechanism, probably an effect on Cl− channels, takes part in the post-receptorial events activated by tachykinin NK1 receptor stimulation in the longitudinal muscle of rabbit colon, and suggest that this mechanism would be more important for generating the sustained tonic than the phasic component of contraction.

The tachykinin NK2 receptor antagonist SR 48968 inhibits citric acid-induced airway hyperresponsiveness in guinea pigs.

Airway hyperresponsiveness is a main feature of asthma, and several lines of evidence suggest that tachykinins might be involved in the pathogenesis of airway hyperresponsiveness in rodents. We conducted a study designed to describe an original model of airway hyperresponsiveness induced by citric acid administered as aerosol to guinea pigs, and to investigate the effects of the nonpeptide neurokinin1 (NK1) and neurokinin2 (NK2)-receptor antagonists, SR 140333 and SR 48968, respectively, on the development of this airway hyperresponsiveness. Animals received thiorphan 1 mg/kg intraperitoneally and 30 min later were exposed to an aerosol of citric acid 0.4 M for 1 h. After 24 h, the animals were anesthetized and ventilated. Airway hyperresponsiveness was evidenced by significant shifts to the left of dose-response curves for intravenous acetylcholine (ACh) without a change in maximum responses to ACh. Exposure to citric acid induced an airway hyperresponsive that was abolished by chronic pretreatment with capsaicin (120 mg/kg, 5 d before citric acid exposure). SR 48968 1 mg/kg intraperitoneally, given once at 30 min before the citric acid exposure, inhibited airway hyperresponsiveness, whereas SR 140333 1 mg/kg or codeine 30 mg/kg given under similar conditions did not. The inhibition of airway hyperresponsiveness by SR 48968 did not result from functional antagonism, since SR 48968 did not affect ACh-induced bronchoconstriction, nor did it result from inhibition of tachykinin, which could have been released under the influence of ACh in hyperresponsive animals, since SR 48968 given after the exposure to aerosolized citric acid failed to inhibit airway hyperresponsiveness. In conclusion, these results show that inhaled citric acid can induce the development of an airway hyperresponsiveness in the guinea pig through a release of tachykinins, and also demonstrate that NK2-receptor stimulation plays a predominant role in the development of airway hyperresponsiveness.

Tachykinin NK2 receptors further characterized in the lung with nonpeptide receptor antagonists.

Two nonpeptide tackykinin NK2 receptor antagonists have now been described, SR 48968 and GR 159897. These drugs are highly specific and very potent antagonists with affinity (binding and in vitro study) for NK2 receptors in the subnanomolar range (pKi = 9-10), without intrinsic activity. They act preferentially on the human NK2A receptor subtype. These drugs exert potent and long-acting antagonism by both i.v. and oral administration. Their use has first confirmed the preponderant role of NK2 receptors in airway smooth muscle contraction, especially in human bronchi. A role for NK2 receptor stimulation has also been clearly demonstrated in bronchoconstriction induced by various agents known to induce the release of tachykinins (capsaicin, resiniferatoxin, citric acid, sodium metabisulfite diethyl ether, serotonin, and bradykinin), in allergen-induced airway constriction in the guinea pig sensitized to ovalbumin, and in hyperpnea-induced bronchoconstriction. Inhibition of neurokinin A mediated or capsaicin-mediated dyspnea by SR 48968 has also been demonstrated in the guinea pig. SR 48968 also is very efficient in inhibiting cough induced by citric acid or capsaicin. Finally, SR 48968 is able to abolish in guinea pigs in vivo the bronchial hyperreactivity induced after 24 or 48 h by a citric acid challenge or an ovalbumin challenge, respectively. Thus, nonpeptide, long-acting NK2 receptor antagonists can be regarded as suitable tools for investigations in humans. They may shortly allow a precise determination of the role of tachykinins in asthmatic patients.